Tempus AI (TEM) vs. Doximity (DOCS): AI Picks the Winner
Key Takeaways
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology. While Doximity remains the dominant digital network for physicians, Tempus AI’s data-intensive approach offers greater long-term disruption across healthcare.
By 2026, Tempus AI is projected to grow revenue by approximately 40% to $1.2 billion, with earnings per share reaching $0.80. Doximity, by comparison, is expected to deliver steadier growth of around 15%, with revenue approaching $600 million and EPS near $1.20. Price forecasts reflect this difference in growth profiles: TEM is expected to average $75 by the end of 2026, with upside potential to $100, while DOCS is forecast to average $50, with highs near $60. Although Tempus trades at a higher forward valuation multiple, that premium reflects its faster growth trajectory and innovation-driven business model.
Tickeron’s AI-powered trading bots further strengthen the case for TEM. Strategies focused on Tempus AI have delivered annualized returns of up to 279%, supported by win rates around 72%, outperforming Doximity-focused strategies that average closer to 200%. Overall, AI-driven analysis favors Tempus AI for its scalability, diagnostic innovation, and superior performance in both fundamentals and algorithmic trading.
Products and Services: Tempus AI vs. Doximity
Tempus AI and Doximity are both leaders in healthcare technology, but they address very different needs within the medical ecosystem. Tempus focuses on AI-driven diagnostics and data analytics, while Doximity centers on professional networking and digital tools for clinicians. As of early 2026, both platforms serve physicians, healthcare systems, and researchers, but with distinct value propositions.
Tempus AI specializes in precision medicine, applying artificial intelligence to large-scale clinical and molecular datasets to support personalized treatment decisions. Its core offerings include genomic sequencing tests for oncology and cardiology, AI platforms such as Tempus One for real-time clinical insights, and expansive data libraries containing millions of de-identified patient records. Tempus also provides services for diagnostic interpretation, clinical trial matching, and research partnerships. In 2025, the company expanded its cardiology-focused AI tools and deepened collaborations in drug discovery, generating revenue through testing services, data licensing, and subscription-based platforms.
Doximity, by contrast, operates a digital professional network used by a majority of U.S. physicians. Its flagship products include the Doximity mobile app for secure messaging, telehealth video visits, and curated medical news, along with tools such as Dialer for virtual patient interactions. The platform also offers recruiting services, continuing medical education credits, and analytics for pharmaceutical marketing. In 2025, Doximity continued to grow its user base and enhanced telehealth integrations, generating revenue primarily from subscriptions, advertising, and telehealth-related services.
While Doximity excels at improving communication and workflow efficiency for clinicians, Tempus AI stands out for its ability to translate complex biological data into actionable medical insights. Financially, Doximity’s 2025 revenue slightly exceeded Tempus AI’s, but Tempus’s focus on AI-driven diagnostics positions it for faster expansion and greater long-term upside.
AI Trading Performance: Tickeron Bots on TEM and DOCS
Tickeron’s AI Trading Bot use advanced financial learning models to analyze real-time market data, sentiment, and technical patterns. These systems deploy strategies such as momentum trading, hedging, and volatility capture, which are particularly effective in innovation-driven healthcare stocks.
For Tempus AI, the bots have been highly effective in capitalizing on announcements related to AI breakthroughs, clinical partnerships, and product expansion. Top-performing strategies delivered annualized returns of up to 279%, with win rates around 72%. Multi-agent hedging strategies produced gains exceeding 170%, while volatility-focused approaches generated outsized returns on leveraged trades. Ensemble models further improved risk-adjusted performance by reducing drawdowns.
Doximity-focused bots also performed well but showed lower peak upside. Average annualized returns were closer to 200%, with win rates near 70%. Strategies tended to benefit from steady user growth and earnings-related catalysts, but the stock’s more mature profile limited explosive upside.
In direct comparison, TEM-focused strategies outperformed DOCS by roughly 30–50%, supported by stronger growth signals and higher Sharpe ratios—an advantage in a rapidly evolving healthcare technology market.
2026 Price Outlook for TEM and DOCS
Price forecasts for 2026 reflect continued optimism in healthcare technology, with Tempus AI positioned as a primary growth beneficiary. TEM is projected to average $75 by year-end, with a trading range between $50 and $100, driven by expanding adoption of AI diagnostics and new clinical applications. Quarterly estimates suggest a gradual rise from $65 in Q1 to $75 by Q4.
Doximity is expected to average $50 in 2026, with a range from $40 to $60, supported by continued physician engagement and telehealth adoption. Quarterly projections indicate steady appreciation from $45 in Q1 to $50 by Q4. Both outlooks assume stable sector conditions, but Tempus AI’s innovation-driven model offers greater upside potential.
Final Verdict: TEM or DOCS?
From an AI-driven perspective, Tempus AI emerges as the preferred choice for 2026. Its leadership in precision medicine, advanced AI-driven diagnostics, and expanding role in personalized healthcare give it a clear edge over Doximity’s more established networking-focused business. While Doximity offers reliable utility and consistent cash flow, its mature profile limits its long-term growth potential.
With TEM projected to average $75 in 2026 and supported by AI trading strategies delivering returns of up to 279%, Tempus AI stands out as the more innovative and scalable healthcare technology investment. Investors seeking exposure to professional medical networking may still favor DOCS, but those prioritizing disruption, data-driven insights, and high-growth potential are likely to align more closely with Tempus AI.
Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TEM sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for TEM moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on TEM as a result. In 30 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
Following a +9.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 110 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 48 of 54 cases where TEM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for TEM moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 14 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 21 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TEM broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (34.722) is very high in comparison to the industry average of (7.432). P/E Ratio (39.298) is within average values for comparable stocks, (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement